Compare · LNSR vs SYK
LNSR vs SYK
Side-by-side comparison of LENSAR Inc. (LNSR) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LNSR and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 1518.2x LNSR ($74.1M).
- Over the past year, LNSR is down 52.3% and SYK is down 22.8% - SYK leads by 29.5 points.
- SYK has hit the wire 7 times in the past 4 weeks while LNSR has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 3 for LNSR).
- Company
- LENSAR Inc.
- Stryker Corporation
- Price
- $5.82-3.96%
- $294.69+0.46%
- Market cap
- $74.1M
- $112.48B
- 1M return
- -18.26%
- +5.16%
- 1Y return
- -52.33%
- -22.78%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 7
- Recent ratings
- 3
- 25
LENSAR Inc.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest LNSR
- SEC Form 10-Q filed by LENSAR Inc.
- LENSAR Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
- LENSAR Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
- SEC Form DEFA14A filed by LENSAR Inc.
- SEC Form DEF 14A filed by LENSAR Inc.
- Director Hammer Todd B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Director Ellis Thomas B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Principal Accounting Officer Wong Kendra was granted 13,066 shares, increasing direct ownership by 30% to 56,481 units (SEC Form 4)
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)